# Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC

> **NCT00544648** · PHASE1,PHASE2 · TERMINATED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** carboplatin
- **DRUG:** nab-paclitaxel
- **RADIATION:** Radiation therapy

## Key facts

- **NCT ID:** NCT00544648
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Ph I completed. Funding became unavailable causing Ph II to cease after two patients were enrolled.
- **Last updated:** 2014-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00544648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00544648, "Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00544648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*